Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 36, 2006, Pages 5786-5788

  Tsai, Kun Ying ^a   Yang, Chih Hsun ^a   Kuo, Tseng Tong ^a   Hong, Hong Shang ^a   Chang, John W C ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE FUROATE; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ADVANCED CANCER; ANAMNESIS; ARTICLE; CANCER PATIENT; CASE REPORT; DESQUAMATION; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; SEBORRHEIC DERMATITIS; SKIN BIOPSY; CHEMICALLY INDUCED DISORDER; ERYTHEMA; FOOT; HAND; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; SYNDROME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DERMATITIS, SEBORRHEIC; ERYTHEMA; FOOT; HAND; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; SYNDROME;

EID: 34247361171     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.6868     Document Type: Article

References (14)

1. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
2. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 353:14-17, 1999
3. Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104:2323-2333, 2005
4. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
5. Clark JW, Eder JP, Ryan D, et al: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480, 2005
6. Yang JC: Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 10:6367S-6370S, 2004
7. Lassere Y, Hoff P: Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8:S31-S40, 2004 (suppl 1)
8. Erber R, Thurnher A, Katsen AD, et al: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18:338-340, 2004
9. Gupta AK, Bluhm R: Seborrheic dermatitis. J Eur Acad Dermatol Venereol 18:13-26, 2004; quiz 19-20, 2004
10. Wiwanitkit V: Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: A note on 120 cases. Int J Dermatol 43:265-268, 2004
11. Oble DA, Collett E, Hsieh M, et al: A novel T cell receptor transgenic animal model of seborrheic dermatitis-like skin disease. J Invest Dermatol 124:151-159, 2005
12. Hall VC, El-Azhary RA, Bouwhuis S, et al: Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 48:548-552, 2003
13. Daynes RA, Dowell T, Araneo BA: Platelet-derived growth factor is a potent biologic response modifier of T cells. J Exp Med 174:1323-1333, 1991
14. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433, 2005